Innate Pharma Net Asset Quality Index
Innate Pharma net asset quality index. Innate Pharma (IPHA) has a Net Asset Quality Index of -34.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $62.69 Million minus total liabilities of $84.39 Million yields net assets of $-21.69 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Innate Pharma book value and equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Innate Pharma (2005–2025)
Net asset quality index of Innate Pharma from 2005 to 2025. This chart shows how Innate Pharma's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of March 2026, the index stands at -34.6%, representing net assets of $-21.69 Million against total assets of $62.69 Million USD. Check strategic asset allocation of Innate Pharma to assess the company's strategic physical and investment asset allocation.
Innate Pharma Net Asset Quality Index by Year (2005–2025)
Innate Pharma net asset quality index by year from 2005 to 2025. The table below presents the year-by-year Net Asset Quality Index for Innate Pharma from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Innate Pharma (IPHA) market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -34.6% | $-21.69 Million | $62.69 Million | $84.39 Million | ▼ -42.6 pp |
| 2024 | 8.0% | $8.83 Million | $111.06 Million | $102.22 Million | ▼ -16.5 pp |
| 2023 | 24.5% | $42.90 Million | $175.19 Million | $132.29 Million | ▼ -1.6 pp |
| 2022 | 26.1% | $54.15 Million | $207.86 Million | $153.71 Million | ▼ -14.1 pp |
| 2021 | 40.2% | $107.44 Million | $267.50 Million | $160.06 Million | ▼ -10.6 pp |
| 2020 | 50.7% | $155.97 Million | $307.42 Million | $151.45 Million | ▼ -3.4 pp |
| 2019 | 54.2% | $217.42 Million | $401.36 Million | $183.94 Million | ▲ +17.1 pp |
| 2018 | 37.1% | $167.24 Million | $451.22 Million | $283.98 Million | ▲ +3.4 pp |
| 2017 | 33.7% | $85.96 Million | $255.02 Million | $169.07 Million | ▲ +3.1 pp |
| 2016 | 30.6% | $86.17 Million | $281.58 Million | $195.41 Million | ▲ +7.0 pp |
| 2015 | 23.6% | $72.07 Million | $305.96 Million | $233.89 Million | ▼ -58.7 pp |
| 2014 | 82.3% | $74.63 Million | $90.69 Million | $16.06 Million | ▲ +10.2 pp |
| 2013 | 72.1% | $40.29 Million | $55.88 Million | $15.60 Million | ▲ +23.7 pp |
| 2012 | 48.4% | $23.36 Million | $48.30 Million | $24.93 Million | ▲ +4.1 pp |
| 2011 | 44.3% | $26.62 Million | $60.11 Million | $33.48 Million | ▼ -25.5 pp |
| 2010 | 69.8% | $33.52 Million | $48.01 Million | $14.49 Million | ▼ -3.6 pp |
| 2009 | 73.4% | $47.12 Million | $64.22 Million | $17.10 Million | ▲ +5.5 pp |
| 2008 | 67.9% | $41.34 Million | $60.86 Million | $19.52 Million | ▼ -10.6 pp |
| 2007 | 78.5% | $49.61 Million | $63.15 Million | $13.55 Million | ▼ -2.8 pp |
| 2006 | 81.4% | $56.37 Million | $69.25 Million | $12.89 Million | ▲ +0.4 pp |
| 2005 | 81.0% | $20.07 Million | $24.77 Million | $4.70 Million | — |